Current Treatment Options in Oncology最新文献_第8页

Advances in the Pathogenesis, Diagnosis, Treatment, and Prognosis of Marginal Zone Lymphoma. 边缘区淋巴瘤的发病机制、诊断、治疗及预后研究进展。

IF 3.8 2区医学

Current Treatment Options in Oncology Pub Date : 2025-02-01 DOI: 10.1007/s11864-025-01293-w

Qingyang Zhang, Wenzhe Yan, Heng Li, Hongling Peng

{"title":"Advances in the Pathogenesis, Diagnosis, Treatment, and Prognosis of Marginal Zone Lymphoma.","authors":"Qingyang Zhang, Wenzhe Yan, Heng Li, Hongling Peng","doi":"10.1007/s11864-025-01293-w","DOIUrl":"10.1007/s11864-025-01293-w","url":null,"abstract":"Opinion statement: The management of marginal zone lymphoma (MZL), an indolent B-cell non-Hodgkin lymphoma, requires a personalized and adaptive approach due to its clinical and prognostic heterogeneity. We believe treatment should emphasize a balanced strategy considering the subtype, disease burden, symptoms, and actionable genetic or environmental factors, such as infections or autoimmune diseases. For asymptomatic patients with low tumor burden or disseminated disease, a watch-and-wait approach remains appropriate, given MZL's indolent nature and the risks of overtreatment. Conversely, for symptomatic or high-burden cases, early intervention with chemoimmunotherapy is recommended for effective disease control. Surgery remains essential for both diagnosis and the treatment of localized disease. Incorporating molecular profiling and prognostic models, such as MZL-IPI and POD24, is crucial for decision-making and risk stratification. Testing for infectious agents like Helicobacter pylori or Hepatitis C virus should be standard practice, as eradication therapy offers a targeted, less toxic, and effective option in select patients. With ongoing advancements in understanding dysregulated signaling pathways and the tumor microenvironment, we anticipate novel targeted therapies and combination regimens will further improve outcomes. We advocate for molecular testing at diagnosis to identify actionable biomarkers, particularly for patients with refractory or relapsed disease. Finally, MZL management requires vigilant follow-up with adjustments based on evolving disease features. Treatment decisions should integrate patient preferences, clinical context, and the latest evidence to maximize survival while preserving quality of life.","PeriodicalId":50600,"journal":{"name":"Current Treatment Options in Oncology","volume":" ","pages":"142-155"},"PeriodicalIF":3.8,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143076294","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The Review of Modified Intersphincteric Resection in the Treatment of Ultra-Low Rectal Cancer. 改良括约肌间切除术治疗超低位直肠癌的研究进展。

IF 3.8 2区医学

Current Treatment Options in Oncology Pub Date : 2025-02-01 Epub Date: 2025-01-23 DOI: 10.1007/s11864-025-01291-y

Danni Li, Xi Xiong, Pan Diao, Jitao Hu, Wenbo Niu, Guiying Wang, Baokun Li

引用次数: 0

Candidate Biomarker of Response to Immunotherapy In Small Cell Lung Cancer. 小细胞肺癌免疫治疗应答的候选生物标志物。

IF 3.8 2区医学

Current Treatment Options in Oncology Pub Date : 2025-02-01 Epub Date: 2025-01-22 DOI: 10.1007/s11864-025-01292-x

Yili Shen, Zhicong Liu, Yi Chen, Xuefei Shi, Shunli Dong, Bin Wang

{"title":"Candidate Biomarker of Response to Immunotherapy In Small Cell Lung Cancer.","authors":"Yili Shen, Zhicong Liu, Yi Chen, Xuefei Shi, Shunli Dong, Bin Wang","doi":"10.1007/s11864-025-01292-x","DOIUrl":"10.1007/s11864-025-01292-x","url":null,"abstract":"Opinion statement: Small-cell lung cancer accounts for about 15% of lung cancers with an extremely poor prognosis. The incorporation of immunotherapy to platinum-based chemotherapy offers sustained overall survival benefits and become the standard for the first-line setting of extensive-stage small-cell lung cancer. However, only a limited number of patients derive prolonged benefits. Although novel immunomodulatory agents and combination strategies are currently under investigation, identifying patients who are likely to obtain clinical benefits from this therapeutic approach is urgently needed. The modest therapeutic response to immunotherapy can be explained by various mechanisms. Traditional biomarkers do not guide immunotherapeutic decision-making in small-cell lung cancer. Notably, recent progress in the understanding of the molecular typing of small-cell lung cancer based on multi-omics data might bring new sights. This review summarizes the potential biomarkers for small-cell lung cancer immunotherapy based on clinical trials and preclinical studies. Moreover, important constraints in identifying biomarkers for small-cell lung cancer treatment are discussed.","PeriodicalId":50600,"journal":{"name":"Current Treatment Options in Oncology","volume":" ","pages":"73-83"},"PeriodicalIF":3.8,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143015657","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Evolving Immunotherapy Strategies in Gastrointestinal Neuroendocrine Neoplasms. 胃肠神经内分泌肿瘤免疫治疗策略的发展

IF 3.8 2区医学

Current Treatment Options in Oncology Pub Date : 2025-02-01 Epub Date: 2025-01-23 DOI: 10.1007/s11864-024-01283-4

Arielle Urman, Ian Schonman, Ana De Jesus-Acosta

{"title":"Evolving Immunotherapy Strategies in Gastrointestinal Neuroendocrine Neoplasms.","authors":"Arielle Urman, Ian Schonman, Ana De Jesus-Acosta","doi":"10.1007/s11864-024-01283-4","DOIUrl":"10.1007/s11864-024-01283-4","url":null,"abstract":"Opinion statement: Treatment for neuroendocrine neoplasms (NENs) is tailored to the tumor's site of origin, grade, and differentiation. NENs are categorized into two main types: well-differentiated neuroendocrine tumors (NETs), which tend to grow more slowly and are less aggressive, and poorly differentiated neuroendocrine carcinomas (NECs), which are highly aggressive and harder to treat. Treatment options for NETs range from somatostatin analogues and mTOR inhibitors to peptide receptor radionuclide therapy (PRRT) with Lutetium-177 dotatate. In cases where the disease progresses more rapidly, cytotoxic chemotherapy may also be considered. In contrast, chemotherapy plays a central role in treating NECs, often following protocols similar to those used for small cell lung cancer. Exciting progress is being made in the development of new therapies for NENs. Inspired by the success of immunotherapy in other cancers, clinical trials have begun to explore its potential in NENs. Early findings suggest that immune checkpoint inhibitors (ICIs) may offer benefits, especially in patients with higher-grade NETs and NECs. However, because NENs have an immunologically \"cold\" tumor microenvironment-meaning they are less likely to trigger an immune response-new strategies are needed to boost ICI efficacy. To overcome this challenge, researchers are exploring innovative approaches, such as combining dual ICIs or pairing ICIs with other therapeutic agents to make the tumors more responsive to immune attack. Moreover, there is growing enthusiasm for cutting-edge therapies designed to enhance the immune system's ability to recognize and destroy cancer cells. These include bispecific T cell engagers, chimeric antigen receptor T cells, tumor-infiltrating lymphocytes, oncolytic viruses, and cancer vaccines. While their effectiveness in NENs is still being studied, these approaches hold considerable promise, offering new hope for patients with this challenging and complex cancer type.","PeriodicalId":50600,"journal":{"name":"Current Treatment Options in Oncology","volume":" ","pages":"92-102"},"PeriodicalIF":3.8,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143025508","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Targets Selection for Precision Therapy of Relapsed/Refractory Multiple Myeloma: the Latest Advancements. 复发/难治性多发性骨髓瘤精准治疗的靶点选择：最新进展

IF 3.8 2区医学

Current Treatment Options in Oncology Pub Date : 2025-02-01 Epub Date: 2025-01-31 DOI: 10.1007/s11864-025-01290-z

Zhen Wang, Yanqi Song, Honglei Guo, Yuting Yan, Lin Ma, Baoshan Liu

{"title":"Targets Selection for Precision Therapy of Relapsed/Refractory Multiple Myeloma: the Latest Advancements.","authors":"Zhen Wang, Yanqi Song, Honglei Guo, Yuting Yan, Lin Ma, Baoshan Liu","doi":"10.1007/s11864-025-01290-z","DOIUrl":"10.1007/s11864-025-01290-z","url":null,"abstract":"Opinion statement: According to the guidelines, the primary treatment for multiple myeloma is still based on drugs such as carfilzomib, lenalidomide, or daratumumab. However, patients with relapsed/refractory multiple myeloma (RRMM) may be insensitive or develop resistance to the above therapeutic medications. Thus, formulating standardized and rational treatment regimens for such patients remains an area for consideration. Multidrug combinations are available for the therapy of patients with relapsed/refractory multiple myeloma to improve their clinical outcome and prevent the occurrence of multidrug resistance. For instance, combination therapy with immunomodulators, proteasome inhibitors, and CD38 monoclonal antibodies. With the development of genomics and molecular diagnostic technologies, RRMM has entered the era of precision therapy. Targeted immunotherapeutic drugs such as monoclonal antibodies, bispecific antibodies, antibody-drug conjugates (ADCs), and chimeric antigen receptor-T (CAR-T) cells have shown promising clinical response rates and favorable safety profiles in several clinical and experimental studies. These cutting-edge medicinal treatments may provide new hope for a cure for RRMM. However, the choice of treatment regimen still needs to adhere to the principle of individualization. Generally, we recommend treatment with drugs of a new generation or novel mechanism of action for patients with RRMM who are first relapsed, such as next-generation proteasome inhibitors, next-generation immunomodulators, and CD38-based monoclonal antibody regimens. For multiple relapsed RRMM, we recommend choosing a combination regimen or participating in relevant clinical trials. Additionally, monoclonal antibodies have become the standard of care for patients with RRMM. With the introduction of CAR-T therapy, ADCs, and bispecific antibodies, RRMM patients are expected to achieve deep remissions and long-term survival again.","PeriodicalId":50600,"journal":{"name":"Current Treatment Options in Oncology","volume":" ","pages":"128-141"},"PeriodicalIF":3.8,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143069377","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A fishnet between nasopharyngeal carcinoma and resistance: the competing endogenous RNA network. 鼻咽癌与耐药之间的渔网：竞争的内源性RNA网络。

IF 3.8 2区医学

Current Treatment Options in Oncology Pub Date : 2025-01-01 Epub Date: 2025-01-15 DOI: 10.1007/s11864-024-01284-3

Mingtai Li, Tongtong Mo, Zisha Yang, Yunhong Yao, Yan Wang, Yi Zhao

引用次数: 0

A Review on Integrating Breast Cancer Clinical Data: A Unified Platform Perspective. 乳腺癌临床数据整合综述：统一平台视角。

IF 3.8 2区医学

Current Treatment Options in Oncology Pub Date : 2025-01-01 Epub Date: 2025-01-03 DOI: 10.1007/s11864-024-01285-2

Ram Mohan Ram Kumar, Suresh Joghee

{"title":"A Review on Integrating Breast Cancer Clinical Data: A Unified Platform Perspective.","authors":"Ram Mohan Ram Kumar, Suresh Joghee","doi":"10.1007/s11864-024-01285-2","DOIUrl":"10.1007/s11864-024-01285-2","url":null,"abstract":"Opinion statement: Integrating clinical datasets in breast cancer research emerges as a necessary tool for advancing our knowledge of the disease and enhancing patient outcomes. Synthesizing diverse datasets offers advantages, from facilitating evidence-based insights to enabling predictive analytics and precision medicine strategies. Crucially, effective integration of clinical datasets necessitates collaborative efforts, policy interventions, and technological advancements to elevate global standards of breast cancer care. This narrative review underscores the imperative and substantial benefits of dataset integration in advancing breast cancer research and optimizing patient management. First, integrating diverse datasets-encompassing patient demographics, tumor characteristics, treatment modalities, and clinical outcomes-can significantly enhance our understanding of the disease's complexities and treatment responses across diverse patient populations. Second, we suggest that regulatory approval processes should allow new treatments to be conditionally approved for patients who were not part of the initial trials. This approval would depend on evaluating how well these treatments perform in real-world situations before full approval is granted. Third, we emphasize the importance of incorporating high-quality real-world evidence into treatment guidelines to better inform patient counselling and optimize personalized treatment strategies.","PeriodicalId":50600,"journal":{"name":"Current Treatment Options in Oncology","volume":" ","pages":"1-13"},"PeriodicalIF":3.8,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142923912","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The Role of Radiotherapy in the Management of Melanoma Brain Metastases: An Overview. 放疗在治疗黑色素瘤脑转移中的作用：概述。

IF 3.8 2区医学

Current Treatment Options in Oncology Pub Date : 2025-01-01 Epub Date: 2025-01-03 DOI: 10.1007/s11864-024-01289-y

Marko Lens, Jacob Schachter

{"title":"The Role of Radiotherapy in the Management of Melanoma Brain Metastases: An Overview.","authors":"Marko Lens, Jacob Schachter","doi":"10.1007/s11864-024-01289-y","DOIUrl":"10.1007/s11864-024-01289-y","url":null,"abstract":"Opinion statement: Clinical management of melanoma brain metastases is complex and requires multidisciplinary approach. With close collaboration between neurosurgeons, radiation oncologists and medical oncologists, melanoma patients with brain are offered different treatment modalities: surgery, radiation therapy, systemic therapy or combined treatments. Radiation therapy (whole brain radiotherapy- WBRT and stereotactic radiosurgery- SRS) is an integral part of treating melanoma brain metastases. Use of immunotherapy (checkpoint inhibitors) and targeted therapy (BRAF/MEK inhibitors) significantly changed the outcome in patients with melanoma metastases. Currently, ipilimumab and nivolumab (COMBO) is the preferred first-line systemic therapy for all patients with asymptomatic brain metastases, regardless of BRAF status (BRAF wild-type and BRAF-mutated). Although at the moment there is no consensus on the concomitant use of SRS and COMBO, results from clinical trials suggest that this combined treatment modality should be considered the standard of care for melanoma patients with brain metastases. However, further clinical research is required to define optimal treatment modalities for routine management of melanoma brain lesions.","PeriodicalId":50600,"journal":{"name":"Current Treatment Options in Oncology","volume":" ","pages":"36-44"},"PeriodicalIF":3.8,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11769869/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142923913","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Central Nervous System Metastases in Breast Cancer. 中枢神经系统在乳腺癌中的转移。

IF 3.8 2区医学

Current Treatment Options in Oncology Pub Date : 2025-01-01 Epub Date: 2025-01-09 DOI: 10.1007/s11864-024-01286-1

Thomas Grinda, Ayal A Aizer, Nancy U Lin, Sarah L Sammons

{"title":"Central Nervous System Metastases in Breast Cancer.","authors":"Thomas Grinda, Ayal A Aizer, Nancy U Lin, Sarah L Sammons","doi":"10.1007/s11864-024-01286-1","DOIUrl":"10.1007/s11864-024-01286-1","url":null,"abstract":"Opinion statement: Breast cancer metastasizing to the central nervous system (CNS) encompasses two distinct entities: brain metastases involving the cerebral parenchyma and infiltration of the leptomeningeal space, i.e., leptomeningeal disease. CNS metastases affect 10-15% of patients with hormone receptor-positive-status and nearly one-half of those with HER2-positive and triple-negative breast cancer with distant metastatic disease. Significant clinical morbidity and heterogeneous penetration of the blood-brain barrier by systemic therapies contribute to the poor prognosis associated with brain metastases. Recent advances in radiotherapy, including stereotactic approaches and morbidity-reducing strategies such as the use of memantine and hippocampal avoidance in whole brain radiation, coupled with the development of more effective CNS-penetrant systemic therapies, including small molecules and antibody-drug conjugates, have significantly improved patient outcomes. Consequently, patients with breast cancer CNS metastases have improved survival compared to prior decades, and longitudinal care has become increasingly complex, necessitating a multidisciplinary approach to achieve optimal outcomes for patients.","PeriodicalId":50600,"journal":{"name":"Current Treatment Options in Oncology","volume":" ","pages":"14-35"},"PeriodicalIF":3.8,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142958328","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Neuroendocrine Tumors: Germline Genetics and Hereditary Syndromes. 神经内分泌肿瘤：种系遗传学和遗传综合征。

IF 4.7 2区医学

Current Treatment Options in Oncology Pub Date : 2025-01-01 Epub Date: 2025-01-17 DOI: 10.1007/s11864-024-01288-z

Eleonora Lauricella, Nada Chaoul, Gabriella D'Angelo, Andrea Giglio, Concetta Cafiero, Camillo Porta, Raffaele Palmirotta

引用次数: 0